Annoroad Gene Technology

Annoroad Gene Technology (Beijing) Co., Ltd., established in 2012, is a platform-based enterprise in China's genomics industry. Since its inception, Annoroad has obtained numerous qualifications and honors, including High-Tech Enterprise, Clinical Application Pilot Unit for High-Throughput Gene Sequencing Technology, Demonstration Center for Gene Testing Technology Application, Specialized and Sophisticated "Little Giant" Enterprise, National Intellectual Property Advantage Enterprise, Beijing Engineering Laboratory, Beijing Enterprise Technology Center, Beijing SME Public Service Demonstration Platform, Capital Civilized Unit, and Zhongguancun Frontier Technology Enterprise, and hosts a post-doctoral research station. Annoroad has been deeply engaged in the two major fields of human medical health and life science research, establishing professional R&D and production platforms, actively promoting the industrial application of gene technology, and contributing to the development of life sciences. Possessing independent innovation capabilities in genome sequencing and bioinformatics, Annoroad continuously advances technology R&D and product transformation. In the medical health field, following technological and industrial trends, Annoroad persistently promotes the registration of medical device products based on high-throughput sequencing technology, and has successfully obtained registration/filing certificates for multiple medical device products, including the NextSeq 550AR Gene Sequencer (National Medical Device Registration No.: 20173220330), the Fetal Chromosomal Aneuploidy Detection Kit (National Medical Device Registration No.: 20173400331), and the Chromosomal Aneuploidy and Gene Microdeletion Detection Kit (National Medical Device Registration No.: 20243400077), contributing to eugenics and superior child-rearing. In the research service field, leveraging its advantages in multi-omics technology, Annoroad conducts extensive research collaborations with domestic and international universities, research institutes, and R&D organizations, and has co-published nearly a thousand high-impact papers in journals such as Nature, Science, Cell, and Nature Genetics. Currently, Annoroad has formed distinctive technical advantages in areas such as single-cell multi-omics, third-generation sequencing, complex genome assembly, and pangenome assembly, providing excellent overall solutions for life science research. In the future, Annoroad will uphold the philosophy of "Enhancing life quality with gene technology and innovation," striving to become a pioneering explorer and leader in continuously providing advanced gene testing products and services.